8f518c0d-42e0-4418-bb48-f69b32446b46
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 71.5811088295688
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.390
- WNT_BETA_CATENIN_SIGNALING+0.390
- HEDGEHOG_SIGNALING+0.310
- APICAL_JUNCTION+0.300
- XENOBIOTIC_METABOLISM+0.250
- IL6_JAK_STAT3_SIGNALING+0.240
- MYOGENESIS+0.230
- ESTROGEN_RESPONSE_EARLY+0.200
- ESTROGEN_RESPONSE_LATE+0.200
- KRAS_SIGNALING_DN+0.200
Top 10 suppressed
- PROTEIN_SECRETION-0.430
- ANDROGEN_RESPONSE-0.400
- G2M_CHECKPOINT-0.300
- E2F_TARGETS-0.280
- UV_RESPONSE_DN-0.270
- MYC_TARGETS_V1-0.230
- APOPTOSIS-0.220
- TNFA_SIGNALING_VIA_NFKB-0.220
- ANGIOGENESIS-0.210
- SPERMATOGENESIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1336 | Med | Medulloblastoma | 0.857 |
| 2 | 1c3d6580-0dc8-4346-a4f7-0bb404d4a245 | — | — | 0.804 |
| 3 | a8235ad1-0c5f-4a0b-b595-85ef3a1e49ff | — | — | 0.793 |
| 4 | 62a2cbf8-51be-469b-978c-bdf386e0d651 | — | — | 0.789 |
| 5 | 18f03a3f-c2d2-4c3b-a246-e8a78e6aa479 | — | — | 0.787 |
| 6 | MNG545 | — | — | 0.781 |
| 7 | fee5651d-3ac9-474a-84da-4fd0ce06f341 | — | — | 0.774 |
| 8 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.772 |
| 9 | ea9f5a96-93d4-4724-bc4b-2813fa8a35ae | — | — | 0.767 |
| 10 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.390 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.150 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.050 | Inavolisib | — uncovered |